Drug · CHEMBL126
LINEZOLID
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LINEZOLID. Drugs and targets, record CHEMBL126. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL126
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 5 of its 30 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases30
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 30Source Open Targets
See all 30 diseasesTrials158
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00084266 | Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA) | Phase 4 | 1,225 | 2011-05-09 | linezolid | Its name | ClinicalTrials.gov |
| NCT00087490 | Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA) | Phase 4 | 1,077 | 2012-08-08 | linezolid | Its name | ClinicalTrials.gov |
| NCT01431339 | Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections | Phase 3 | 739 | 2014-02-12 | linezolid | Its name | ClinicalTrials.gov |
| NCT02877927 | Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI | Phase 3 | 735 | 2018-11-30 | linezolid | Its name | ClinicalTrials.gov |
| NCT01170221 | TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. | Phase 3 | 667 | 2014-09-03 | linezolid | Its name | ClinicalTrials.gov |
| NCT02378480 | Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23) | Phase 3 | 655 | 2019-03-21 | linezolid | Its name | ClinicalTrials.gov |
| NCT02066402 | Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) | Phase 3 | 598 | 2017-06-07 | linezolid | Its name | ClinicalTrials.gov |
| NCT00852540 | Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA | Phase 3 | 410 | 2011-08-26 | linezolid | Its name | ClinicalTrials.gov |
| NCT01283581 | A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections | Phase 2 | 256 | 2013-10-29 | linezolid | Its name | ClinicalTrials.gov |
| NCT02619994 | Treatment Shortening of MDR-TB Using Existing and New Drugs | Phase 2 | 214 | 2025-01-03 | linezolid | Its name | ClinicalTrials.gov |
1 to 10 of 158
See all 158 trialsComparisons in its trials66
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Linezolid vs Vancomycin: serious adverse events | 145 of 597 | 141 of 587 | 1,184 | NCT00084266 | Trial comparisons |
| Linezolid vs Vancomycin: serious adverse events | 31 of 537 | 32 of 515 | 1,052 | NCT00087490 | Trial comparisons |
| Linezolid-without Concomitant Drugs vs Linezolid-with Concomitant Drugs: Factors Considered to Affect the Safety of Linezolid - Concomitant Drugs. | 9 of 97 | 154 of 873 | 970 | NCT00666276 | Trial comparisons |
| Linezolid Without Renal Dysfunctions vs Linezolid- With Renal Dysfunctions: Factors Considered to Affect the Safety of Linezolid - Renal Dysfunctions. | 125 of 765 | 38 of 205 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-without Hepatic Dysfunctions vs Linezolid- With Hepatic Dysfunctions: Factors Considered to Affect the Safety of Linezolid - Hepatic Dysfunctions. | 137 of 856 | 26 of 114 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-administrated Over 15 Days vs Linezolid-administrated Less Than 15 Days: Factors Considered to Affect the Safety of Linezolid - Duration of Drug Administration. | 53 of 203 | 110 of 767 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-without Non-drug Therapies vs Linezolid-with Non-drug Therapies: Factors Considered to Affect the Safety of Linezolid - Non-drug Therapies. | 87 of 610 | 76 of 360 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-male vs Linezolid-female: Factors Considered to Affect the Safety of Linezolid - Gender. | 109 of 662 | 54 of 308 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-over 65 vs Linezolid-less Than 65: Factors Considered to Affect the Safety of Linezolid - Age | 122 of 688 | 41 of 282 | 970 | NCT00666276 | Trial comparisons |
| Linezolid -Over 40kg vs Linezolid -Less Than 40kg: Factors Considered to Affect the Safety of Linezolid - Weight. | 108 of 651 | 20 of 96 | 747 | NCT00666276 | Trial comparisons |
1 to 10 of 66
See all 66 comparisons in its trialsPapers from its trials163
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Category Fluency | 2 | 0 | ConductCognition |
| Verbal Learning | 2 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL126
GET https://conductscience.org/api/drugs/v1/CHEMBL126/diseases?page=2